| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | 0.086 | 0.009 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | 0.091 | 0.009 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.094 | 0.009 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.095 | 0.01 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.01 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | -0.099 | 0.01 |
| mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | 0.092 | 0.01 |
| mRNA | JNJ-26854165 | GDSC1000 | pan-cancer | AAC | 0.085 | 0.01 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | 0.081 | 0.01 |
| mRNA | Bleomycin | GDSC1000 | pan-cancer | AAC | 0.09 | 0.01 |